R. Xu

发表

Antibody Fab‐Fc properties outperform titer in predictive models of SIV vaccine‐induced protection

J. Weiner, C. Bailey-Kellogg, D. Montefiori, 2019, Molecular systems biology.

Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial

Shuying S Li, M. McElrath, J. McElrath, 2018, PloS one.

The catalytic A1 domains of cholera toxin and heat-labile enterotoxin are potent DNA adjuvants that evoke mixed Th1/Th17 cellular immune responses

M. Egan, K. Bagley, Jennifer A. Schwartz, 2015, Human vaccines & immunotherapeutics.

Vaccinia Virus Infection of Mice Cellular and Humoral Immunity against Bevan

Aaron J. Johnson, D. Liggitt, M. Bevan, 2004 .

High levels of Daxx due to low cellular levels of HSP25 in murine cancer cells result in inefficient adenovirus replication

Jihyun Lee, J. Song, Zhezhu Han, 2019, Experimental & Molecular Medicine.

Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge

T. Rudge, C. Sabourin, J. Eldridge, 2017, Journal of Virology.

Single dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus

J. Eldridge, C. Mire, D. Clarke, 2015, Nature.

Adenovirus-mediated PEDF expression inhibits prostate cancer cell growth and results in augmented expression of PAI-2

M. Guan, Haowen Jiang, Chong Xu, 2007, Cancer biology & therapy.

Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.

L. Stamatatos, N. Letvin, J. Heeney, 2006, Virology.

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for a soluble glycoprotein vaccine to prevent disease caused by Nipah or Hendra viruses.

A. Dimitrov, J. Eldridge, M. Egan, 2021, Vaccine.

Prime-Boost Vaccination with Recombinant Mumps Virus and Recombinant Vesicular Stomatitis Virus Vectors Elicits an Enhanced Human Immunodeficiency Virus Type 1 Gag-Specific Cellular Immune Response in Rhesus Macaques

E. Emini, J. Eldridge, D. Clarke, 2009, Journal of Virology.

Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death

H. Feldmann, C. Happi, J. Eldridge, 2019, The Journal of clinical investigation.

Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein.

L. Stamatatos, Z. Kraft, I. Srivastava, 2006, AIDS research and human retroviruses.

Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.

J. Eldridge, Susan E. Witko, D. Clarke, 2020, The Lancet. Infectious diseases.

Single-Shot ChAd3-MARV Vaccine in Modified Formulation Buffer Shows 100% Protection of NHPs

N. Sullivan, T. Rudge, M. Gazi, 2022, Vaccines.

S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates

Yong-tang Zheng, Chenyan Zhao, Xueqin Huang, 2020, Nature Communications.

Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines.

D. Weiner, G. Pavlakis, M. Sidhu, 2008, Vaccine.

Modifying the HIV-1 env gp160 gene to improve pDNA vaccine-elicited cell-mediated immune responses.

Larry R. Smith, D. Weiner, G. Pavlakis, 2008, Vaccine.

Broad neutralization against SARS-CoV-2 variants induced by a modified B.1.351 protein-based COVID-19 vaccine candidate

Qianqian Wang, G. Siber, D. Ambrosino, 2021, bioRxiv.

Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus

H. Feldmann, A. Marzi, J. Eldridge, 2015, The Journal of infectious diseases.

Broad-Based Influenza-Specific CD8+ T Cell Response without the Typical Immunodominance Hierarchy and Its Potential Implication

N. Mifsud, Cristina F. Triffon, Weisan Chen, 2021, Viruses.

Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection

D. Montefiori, R. Zagursky, C. Labranche, 2015, Proceedings of the National Academy of Sciences.

A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection

M. Proschan, T. Chun, J. Justement, 2017, Science Translational Medicine.

Cellular and Humoral Immunity against Vaccinia Virus Infection of Mice 1

Aaron J. Johnson, D. Liggitt, M. Bevan, 2004, The Journal of Immunology.

Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trial.

D. Montefiori, I. Frank, G. Ferrari, 2023, Vaccine.

An Interleukin 12 Adjuvanted Herpes Simplex Virus 2 DNA Vaccine Is More Protective Than a Glycoprotein D Subunit Vaccine in a High-Dose Murine Challenge Model

W. Halford, J. Eldridge, H. Andersen, 2017 .

Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPVPOS Cancers

S. Russell, K. Peng, J. Eldridge, 2018, Molecular therapy oncolytics.

DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA

R. Gottardo, N. Frahm, Greg Finak, 2017, Clinical and Vaccine Immunology.

Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines.

D. Weiner, G. Pavlakis, M. Sidhu, 2008, Vaccine.